• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Csl Ltd ADR (OP: CSLLY )

    93.50 -1.44 (-1.52%)
    Streaming Delayed Price Updated: 3:59 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Csl Ltd ADR

    Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
    Via Benzinga
    GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
    The U.S. government collaborates with GSK, Sanofi, and CSL to enhance bird flu vaccine production. This initiative aims to increase vaccine readiness to 10 million doses by early 2025 amid rising H5... 
    Via Benzinga
    Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
    CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity compared to Pfizer's Comirnaty in a Phase 3 study, persisting for one year and at a... 
    Via Benzinga
    Exposures COVID-19
    FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
    FDA approves Pfizer's Beqvez for adults with hemophilia B, offering a one-time treatment to produce FIX. Experience reduced bleeding frequency. Explore Pfizer's warranty program. 
    Via Benzinga
    Exposures Product Safety
    Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside
    Canaccord Genuity has initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), a player in the genetic medicine space. 
    Via Benzinga
    Arcturus Shares Jump After Collaboration With CSL For mRNA-Based Vaccines
    Via Benzinga
    CSL Posts Encouraging Data From Garadacimab In Severe Swelling Attacks
    Via Benzinga
    Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
    Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions. 
    Via Investor's Business Daily
    Exposures Product Safety
    5 Diverse Medical Stocks To Buy For 2023 And Beyond
    Healthcare will always be essential to society, making many health companies viable investments for growth. A look at the five top-rated stocks that investors may want to consider buying for 2023 and... 
    Via Talk Markets
    Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories
    Reuters 
    Via Benzinga
    Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case'
    Via Benzinga
    Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
    Via Benzinga
    FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults
    Via Benzinga
    Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today?
    The run-up in ARCT stock is practically unstoppable as two science-focused firms collaborate to develop mRNA technology. 
    Via InvestorPlace
    Travere, CSL's Sparsentan Application Is Under European Review For Rare Kidney Disorder
    Via Benzinga
    The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    CSL Seals $11.7B Buyout Deal Of Vifor Pharma, Probably the Largest Healthcare Deal In 2021
    Australian biopharma CSL Ltd (OTC: CSLLY) has agreed to acquire Vifor Pharma AG (OTC: GNHAY) for $11.7 billion (equity value) in a move to diversify... 
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.